Censavudine (INN; development code BMS-986001 in Bristol Myers-Squibb, OBP-601 in Oncolys Biopharma Inc. and TPN-101 in Transposon Therapuetics, Inc.) is an investigational new drug being developed by Bristol Myers-Squibb for the treatment of HIV infection. It was originally developed at Yale University. It is still in an investigational phase of development as of 2023.
Renaming Until 2013, censavudine has been known as festinavir, but the name was changed to avoid confusion with HIV protease inhibitors which all bear class suffix "–navir" (e.g. tipranavir, lopinavir, saquinavir, etc.).
References